On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10 sites), Phase 2 trial (NCT04412057) of the human anti-LIGHT (TNFSF14) monoclonal antibody CERC-002.

The final analysis inclusive of the 60-day safety update demonstrated the trial met its primary efficacy endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo in COVID-19 patients with ARDS treated with a single dose of the anti-LIGHT monoclonal antibody.